FDA halts sale of painkiller Palladone

The FDA said it had not received reports of major problems with the painkiller, which went on the market in February, but data from a Purdue Pharma study suggested that when Palladone was taken with alcohol, it could disable the drug's gradual-release mechanism and cause serious and perhaps fatal reactions. The suspension is a blow to Purdue Pharma, which had counted on Palladone to replace its blockbuster drug OxyContin, which is facing generic competition. A Purdue spokesperson said that, while the FDA action was "unanticipated," the company "complied with their request."

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC